Breaking News
Get 45% Off 0
🌊 NVIDIA ripple effect: Track AI stocks' response to chip giant's earnings
Explore AI Stocks

Puma Biotech (PBYI) Down 44% Since Last Earnings Report: Can It Rebound?

By Zacks Investment ResearchStock MarketsMar 20, 2020 11:30PM ET
www.investing.com/analysis/puma-biotech-pbyi-down-44-since-last-earnings-report-can-it-rebound-200517925
Puma Biotech (PBYI) Down 44% Since Last Earnings Report: Can It Rebound?
By Zacks Investment Research   |  Mar 20, 2020 11:30PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
US500
-0.91%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

It has been about a month since the last earnings report for Puma Biotech (PBYI). Shares have lost about 44% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Puma Biotech due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.

Puma Biotech Q4 Earnings & Revenues Beat

Puma Biotech incurred a loss of 29 cents per share in the fourth quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of 48 cents as well as the year-ago loss of 80 cents per share.

The loss per share includes an impact of stock-based compensation expense. Excluding such impact, adjusted earnings per share were 1 cent per share versus a loss of 32 cents in the year-ago quarter.

Total revenues consisted of net product revenues from the sales of Nerlynx, license and royalty revenues. In the fourth quarter of 2019, total revenues were $62.9 million, comprising $58.7 million of product revenues from Nerlynx, $0.2 million of royalty revenues from licensing partners and license revenues of $4.0 million. Sales beat the Zacks Consensus Estimate of $57.0 million but were lower than the year-ago figure of $71.1 million.

Quarter in Detail

Sales of Nerlynx declined 3.9% year over year but rose 9.7% on a sequential basis. Nerlynx’s bottle volumes rose 5% sequentially in the quarter. However, new prescriptions declined 16.5% sequentially while total prescription declined 3.3% in the quarter due to lower patient enrolments during the Christmas holiday season.

Total operating costs in the quarter were $71.6 million, down 20.2% year over year.

Research and development expenses (including for stock-based compensation expense) were $31.3 million in the quarter, down 23.7% from the year-ago period.

Selling, general and administrative expenses (including for stock-based compensation expense) declined 21.3% year over year to $30.2 million.

As of Dec 31, 2019, Puma Biotech had cash and cash equivalents of $111.6 million compared with $165.4 million as of Dec 31, 2018.

How Have Estimates Been Moving Since Then?

Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.



Puma Biotechnology, Inc. (PBYI): Free Stock Analysis Report

Original post

Puma Biotech (PBYI) Down 44% Since Last Earnings Report: Can It Rebound?
 

Related Articles

Puma Biotech (PBYI) Down 44% Since Last Earnings Report: Can It Rebound?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email